HAIM
MRKR icon

Hunter Associates Investment Management’s Marker Therapeutics MRKR Stock Holding History

Hunter Associates Investment Management’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-10,000
Closed -$511K – 173
2019
Q3 		$511K Buy
+10,000
New +$591K 0.18% 100

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Hunter Associates Investment Management's MRKR Position: Q4 2019 in Review

Hunter Associates Investment Management sold out of Marker Therapeutics (MRKR) in Q4 2019, closing a stake of 10,000 shares — an estimated $511K sold.

Hunter Associates Investment Management first reported a position in MRKR in Q3 2019 and held it in 1 quarter. The position peaked at $511K in Q3 2019. 65 funds tracked by Wall St. Rank hold MRKR as of Q4 2019.

  • Hunter Associates Investment Management reported no remaining Marker Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Hunter Associates Investment Management sold 10,000 Marker Therapeutics shares in Q4 2019, an estimated $511K.
  • Hunter Associates Investment Management first reported a position in Marker Therapeutics in Q3 2019 and held it in 1 quarter.
  • Hunter Associates Investment Management's Marker Therapeutics position peaked at $511K in Q3 2019.
  • 65 funds tracked by Wall St. Rank held Marker Therapeutics as of Q4 2019.

Based on Hunter Associates Investment Management's 13F filing for Q4 2019, filed 7 Feb 2020.